The Transformative, Alarming Power of Gene Editing
By Dana Goodyear,
The New Yorker
| 09. 02. 2023
A rogue scientist showed that crispr gives humans the ability to transform ourselves. But should we?
He Jiankui, a young Chinese scientist known to his American colleagues as JK, dreamed of remaking humanity by exploiting the emergent technology of gene editing. He had academic polish, and an aptitude for securing institutional support. As a student, he had left China for the United States, where he did graduate work in physics at Rice and a postdoc in a bioengineering lab at Stanford. At the age of twenty-eight, he was recruited into a prestigious Chinese government program for foreign-educated talent, and was offered a founding position in the biology department of the Southern University of Science and Technology.
SUSTech was a newly created research institute in Shenzhen, a city in the midst of a biotech boom. JK, who arrived in 2012, likened Shenzhen’s startup culture to that of Silicon Valley—bold creativity was encouraged, and there was plenty of capital on hand. With colleagues from his lab, he often held brainstorming sessions at a café near campus, delineating his plans. In the first ten years, he would tackle a variety of genetic diseases; in the ten years after that...
Related Articles
By Mike McIntire, The New York Times | 01.24.2026
Genetic researchers were seeking children for an ambitious, federally funded project to track brain development — a study that they told families could yield invaluable discoveries about DNA’s impact on behavior and disease.
They also promised that the children’s sensitive...
By Arthur Lazarus, MedPage Today | 01.23.2026
A growing body of contemporary research and reporting exposes how old ideas can find new life when repurposed within modern systems of medicine, technology, and public policy. Over the last decade, several trends have converged:
- The rise of polygenic scoring...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...